Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Fulgent Genetics (NASDAQ:FLGT) Inc on Tuesday, setting a price target of $126, which is approximately 30.43% above the present share price of $96.6.
DeGeeter expects Fulgent Genetics Inc to post earnings per share (EPS) of $6.55 for the second quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Fulgent Genetics, with an average price target of $107.
The analysts price targets range from a high of $140 to a low of $55.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $294.98 million and a net profit of $225.91 million. The company's market cap is $2.91 billion.
According to TipRanks.com, Oppenheimer analyst Kevin DeGeeter is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 52.8% and a 54.22% success rate.
Fulgent Genetics, Inc. is a technology company, which focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.